Development, Characterization, Efficacy and Mode of Action of Ambisome, A Unilamellar Liposomal Formulation of Amphotericin B

References

• Utz J. P. Amphotericin B toxicity: general side effects. Annals of Internal Medicine. 1964; 61: 340
   PubMed Web of Science ®Google Scholar
• McCurdy D. K., Frederic M., Elkinton J. R. Renal tubular acidosis due to amphotericin B. New England Journal of Medicine. 1968; 278: 124
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Mehta R., Hopfer R. L., Mills K., Kasi L., Mehta K., et al. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. Journal of Infectious Diseases. 1983; 147: 939
   PubMed Web of Science ®Google Scholar
• Lopez-Berestein G., Fainstein V., Hopfer R., Mehta K., Sullivan M. P., Keating M., et al. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. Journal of Infectious Diseases. 1985; 151: 704
   PubMed Web of Science ®Google Scholar
• Payne N. I., Cosgrove R. F., Green A. P., Liu L. In vivo studies of amphotericin B liposomes derived from proliposomes: effect of formulation on toxicity and tissue disposition of the drug in mice. Journal of Pharmacy and Pharmacology. 1987; 39: 24
   PubMed Web of Science ®Google Scholar
• Payne N. I., Browning I., Hynes C. A. Characterization of proliposomes. Journal of Pharmaceutical Sciences. 1986; 75: 330
   PubMed Web of Science ®Google Scholar
• Janoff A. S., Boni L. T., Popescu M. C., Minchey S. R., Cullis P. R., Madden T. D., et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proceedings of the National Academy of Sciences USA. 1988; 85: 6122
   PubMed Web of Science ®Google Scholar
• Szoka F. C., Milholland D., Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrobial Agents and Chemotherapy. 1987; 31: 421
   PubMed Web of Science ®Google Scholar
• Sculier J.-P., Coune A., Meunier F., Brassinne C., Laduron C., Hollaert C., et al. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. European Journal of Cancer and Clinical Oncology. 1988; 24: 527
   PubMedGoogle Scholar
• Papahadjopoulos D., Cowden M., Kimelberg H. Role of cholesterol in membranes. Effects of phospholipid-protein interactions, membrane permeability and enzymatic activity. Biochimica et Biophysica Acta. 1973; 330: 8
   PubMedGoogle Scholar
• Papahadjopoulos D., Jacobson K., Nir S., Isac T. Phase transitions in phospholipid vesicles. Fluorescence polarization and permeability measurements concerning the effect of temperature and cholesterol. Biochimica et Biophysica Acta. 1973; 311: 330
   Google Scholar
• Medoff G., Brajtburg J., Kobayashi G. S., Bolard J. Antifungal agents useful in therapy of systemic fungal infections. Annual Review of Pharmacology and Toxicology. 1983; 23: 303
   PubMed Web of Science ®Google Scholar
• Gamble R. C. Method for preparing small vesicles using microemulsification. U. S. Patent No. 4,753,788, 1988
   Google Scholar
• AmBisome for injection. Package Insert, Vestar, Inc., San Dimas, Ca Dec., 1991
   Google Scholar
• Proffitt R. T., Adler-Moore J., Fujii G., Satorius A., Lee M. J. A., Bailey A. Stability and mode of action of AmBisome (Liposomal Amphotericin B). Abstract in Sixth International Symposium On Recent Advances In Drug Delivery Systems, Salt Lake City, Utah, 1993; 183
   Google Scholar
• Gregoriadis G. Overview of liposomes. Journal of Antimicrobial Chemotherapy 1991; 28(Suppl. B)39
   PubMed Web of Science ®Google Scholar
• McAndrews B. J., Lee M. J. A., Adler-Moore J. P. Comparative toxicities of Fungizone and AmBisome for cultured kidney cells and macrophages. Abstract in 93rd General Meeting for American Society for Microbiology, Atlanta, Georgia, 1993; 11
   Google Scholar
• Little J. R., Abegg A., Plut E. The relationship between adjuvant and mitogenic effects of amphotericin methyl ester. Cellular Immunology. 1983; 78: 224
   PubMed Web of Science ®Google Scholar
• Stein S. H., Little J. R., Little K. D. Parallel inheritance of tissue catalase activity and immunostimulatory action of amphotericin B in inbred mouse strains. Cellular Immunology. 1987; 105: 99
   PubMed Web of Science ®Google Scholar
• Proffitt R. T., Satorius A., Chiang S., Sullivan L., Adler-Moore J. P. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. Journal of Antimicrobial Chemotherapy 1991; 28(Suppl. B)49
   PubMed Web of Science ®Google Scholar
• Lilja H. S., Hall R. L., Alsaker R. D., Wetter T. J. A 30-day toxicity and toxicokinetic study of intravenously administered AmBisome (liposomal Amphotericin B) in beagle dogs. Sponsored by Fujisawa Pharmaceutical Company. Performed at Hazleton Wisconsin, Inc. 1992
   Google Scholar
• Fielding R. M., Singer A. W., Wang L. H., Babbar S., Guo L. S. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrobial Agents and Chemotherapy. 1992; 36: 299
   PubMed Web of Science ®Google Scholar
• Gondal J. A., Swartz R. P., Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrobial Agents and Chemotherapy. 1989; 33: 1544
   PubMed Web of Science ®Google Scholar
• Abra R. M., Hunt C. A. Liposome disposition in vivo. III. Dose and vesicle-size effects. Biochimica et Biophysica Acta. 1981; 666: 493
   PubMed Web of Science ®Google Scholar
• Fromtling R. A., Galgiani J. N., Pfaller M. A., Espinel-Ingroff A., Bartizal K. F., Bartlett M. S., et al. Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrobial Agents and Chemotherapy. 1993; 37: 39
   PubMed Web of Science ®Google Scholar
• Anaissie E., Paetznick V., Proffitt R., Adler-Moore J., Bodey G. P. Comparison of the in vitro anti-fungal activity of free and liposome encapsulated amphotericin B. European Journal of Clinical Microbiology and Infectious Diseases. 1991; 10: 665
   PubMed Web of Science ®Google Scholar
• Clemons K. V., Stevens D. A. Therapeutic efficacy of liposomal formulation of amphotericin B, AmBisome, against murine blastomycosis. Journal of Antimicrobial Chemotherapy 1993, In press
   PubMed Web of Science ®Google Scholar
• Clemons K. V., Stevens D. A. Comparison of a liposomal amphotericin B formulation (AmBisome) and deoxycholate amphotericin B (Fungizone) for the treatment of murine paracoccidioidomycosis. Journal of Medical and Veterinary Mycology 1993, In press
   Google Scholar
• Adler-Moore J., Fujii G., Lee M. J. A., Satorius A., Bailey A., Proffitt R. In vitro, in vivo interactions of AmBisome with pathogenic fungi. Journal of Liposome Research 1993; 3: 151
   Google Scholar
• Cua D. J., Wetzel S. A., Adler-Moore J. P., Sperry P. J. Response of fungal-infected epidermal Langerhans cells to liposome-encapsulated and unencapsulated amphotericin B. Abstract in National Meeting of the Society for Investigative Dermatology. 1991
   Google Scholar
• Wetzel S. A. Studies of the phagocytic capabilities of cultured epidermal Langerhans cells and subsequent fungicidal activity after incubation with free and liposome encapsulated amphotericin B. Masters Thesis, California State Polytechnic University, Pomona 1992
   Google Scholar
• Albert M., Stahl-Carroll T., Graybill J. Comparison of AmBisome (Abs) to amphotericin B (AMB) in cryptococcal meningitis (CM). Abstract in 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992; 140
   Google Scholar
• VanEtten E. W. M., vanden Heuvel C., Bakker-Woudenberg I. A. J. M. Toxicity and efficacy in systemic candidiasis in leukopenic mice of amphotericin B-desoxycholate (Fungizone*) versus liposomal amphotericin B (AmBisome*). Journal of Liposome Research. 1993; 3: 154
   Google Scholar
• Croft S. L., Davidson R. N., Thorton E. A. Liposomal amphotericin B in the treatment of visceral leishmaniasis. Journal of Antimicrobial Chemotherapy 1991; 28(Suppl. B)111
   PubMed Web of Science ®Google Scholar
• Adler-Moore J. P., Chiang S., Satorius A., Guerra D., McAndrews B., McManus E. J., Proffitt R. T. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). Journal of Antimicrobial Chemotherapy 1991; 28(Suppl. B)63
   PubMed Web of Science ®Google Scholar
• Francis P., Lee J., Hoffman A., Peter J., Francesconi A., Bacher J., et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenaic rabbits: the potential role of D-mannitol and galactomannan as markers of infection and therapeutic response. Journal of Infectious Diseases 1993, In press
   Web of Science ®Google Scholar
• Adler-Moore J. In vivo, in vitro evidence for reduced toxicity and mode of action of AmBisome. Bone Marrow Transplantation 1993, Li press
   Web of Science ®Google Scholar
• Katz N. M., Pierce P. F., Anzeck R. A., Visner M. S., Canter H. G., Foegh M. L., et al. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. Journal of Heart Transplantation. 1990; 9: 14
   PubMedGoogle Scholar
• Tollemar J., Ringdén O., Tydén G. Liposomal amphotericin-B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clinical Transplantation. 1990; 4: 167
   Web of Science ®Google Scholar
• Ringden O., Meunier F., Tollemar J., Ricci P., Tura S., Kuse E., et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy 1991; 28(suppl B)73
   PubMed Web of Science ®Google Scholar
• Meunier F., Prentice H. G., Ringdén O. Liposomal amphotericin B (AmBisome): Safety data from a phase II/III clinical trial. Journal of Antimicrobial Chemotherapy 1991; 28(Suppl B)83
   PubMedGoogle Scholar
• Zoubek A., Emminger W., Emminger-Schmidmeier W., Peters C., Pracher E., Grois N., Gadner H. Conventional vs. liposomal amphotericin B in immunosuppressed children. Pediatric Hematology and Oncology. 1992; 9: 187
   PubMed Web of Science ®Google Scholar
• Lackner H., Schwinger W., Urban C., Müller W., Ritschl E., Reiterer F., et al. Liposomal amphotericin-B (AmBisome) for treatment of disseminated fungal infections in two infants of very low birth weight. Pediatrics. 1992; 89: 1259
   PubMed Web of Science ®Google Scholar
• Fisher E. W., Toma A., Fisher P. H., Cheesman A. D. Rhinocerebral mucormycosis: Use of liposomal amphotericin B. The Journal of Laryngology and Otology. 1991; 105: 575
   PubMed Web of Science ®Google Scholar
• Viviani M. A., Cofrancesco E., Boschetti C., Tortorano A. M., Cortellaro M. Eradication of Fusarium infection in a leukopenic patient treated with liposomal amphotericin B. Mycoses. 1991; 34: 255
   PubMed Web of Science ®Google Scholar
• Schürmann D., De Matos Marques B., Grünewald T., Pohle H. D., Hahn H., Ruf B. Safety and efficacy of liposomal amphotericin B in treating ATDS-associated disseminated cryptococcosis. Journal of Infectious Diseases. 1991; 164: 620
   PubMed Web of Science ®Google Scholar
• Coker R. J., Viviani M., Gazzard B. G., DuPont B., Pohle H. D., Murphy S. M., et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS. 1993; 7: 829
   PubMed Web of Science ®Google Scholar
• Chopra R., Fielding A., Goldstone A. H. Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin B (AmBisome) - A report on 40 cases from a single centre. Leukemia and Lymphoma 1992; 7(Suppl.)73
   PubMedGoogle Scholar